XML 23 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheet Components
3 Months Ended
Mar. 31, 2025
Balance Sheet Components  
Balance Sheet Components

6. Balance Sheet Components

Allowance for Expected Credit Losses

The following is a roll-forward of the allowances for expected credit losses related to trade accounts receivable for the three months ended March 31, 2025 and 2024:

Three Months Ended

    

March 31, 

2025

2024

(in thousands)

Beginning balance

$

7,259

$

6,481

Provision for expected credit losses

195

929

Write-offs

(20)

(158)

Total

$

7,434

$

7,252

Property and Equipment, net

The Company’s property and equipment consists of the following:

March 31, 

December 31, 

Useful Life

2025

    

2024

(in thousands)

Machinery and equipment

3-5 years

$

129,005

$

117,076

Computer equipment

3 years

3,287

 

3,178

Purchased and capitalized software held for internal use

3 years

14,587

13,178

Leasehold improvements

Lesser of useful life or lease term

48,883

 

48,569

Construction-in-process

71,271

 

58,461

267,033

 

240,462

Less: Accumulated depreciation and amortization

(86,580)

 

(78,416)

Total property and equipment, net

$

180,453

$

162,046

The Company’s long-lived assets are located in the United States.

Depreciation expense for the three months ended March 31, 2025 and 2024 was $8.2 million and $6.3 million, respectively. The Company did not incur any impairment charges during either period.

Other Accrued Liabilities

The Company’s other accrued liabilities consisted of the following:

March 31, 

    

December 31, 

 

2025

    

2024

 

(in thousands)

 

Reserves for refunds to insurance carriers

$

10,171

$

11,276

Accrued charges for third-party testing

16,963

12,321

Testing and laboratory materials from suppliers

10,754

7,893

Marketing and corporate affairs

17,898

16,548

Legal, audit and consulting fees

66,097

 

54,208

Accrued shipping charges

1,945

1,625

Sales and income tax payable

5,602

4,416

Accrued third-party service fees

8,812

9,046

Clinical trials and studies

 

10,788

10,097

Operating lease liabilities, current portion

12,199

10,168

Property and equipment purchases

9,525

7,098

Other accrued expenses

 

7,695

2,197

Total other accrued liabilities

$

178,449

$

146,893

Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers, and additional amounts that the Company estimates for potential refund requests during the period. When and if these previously accrued amounts are no longer required based on actual refunds requested, any remaining reserve amounts are released. When the Company releases these previously accrued amounts, they are recognized as product revenues in the statements of operations and comprehensive loss.

The following table summarizes the reserve balance and activities for refunds to insurance carriers for the three months ending March 31, 2025 and 2024:

March 31, 

2025

    

2024

(in thousands)

Beginning balance

$

11,276

$

23,245

Additional (reversals) reserves

 

(622)

 

227

Refunds to carriers

 

(3,095)

Reserves released to revenue

(483)

(2,354)

Ending balance

$

10,171

$

18,023